Is Kodak having a "Kodak moment?" 2 watchlist stocks.
Eastman Kodak (KODK) reported 18% YOY revenue growth to $311M, with print and advanced materials segments up 10% and 40% respectively. Gross margin improved 700 bps to 26%, and operational EBITDA grew to $36M. The company is exploring new markets like EV batteries and pharma reagents. NeurAxis (NRXS) also shows potential with high gross margins and product traction.
How this was made
The 30-second read
Why it matters
Both companies show encouraging financial metrics, but scale and sustainability remain uncertain.
Market read
Earnings highlight potential upside for turnaround and niche biotech plays, offering modest trading ideas.
What to watch
Potential cash flow constraints and reliance on niche markets could limit upside.
Background
Kodak is attempting a turnaround after years of decline, while NeurAxis is a small biotech with recent pricing strength.
Ticker impact
Kodak reported Q2 revenue up 18% YoY to $311M with print up 10% and AMC segment up 40%, indicating operational improvement.
Potential modest price appreciation on continued margin expansion.
Revenue and margin growth are material but scale is modest; market may price in incremental upside.
NeurAxis posted 28% YoY price increase and 85.9% gross margin, highlighting strong pricing power and asset efficiency.
Likely continued bullish sentiment, possible short‑term rally.
High gross margin and price growth are encouraging, but company remains small and volatile.
Market effects
Improved performance may lift broader imaging and specialty chemicals sectors.
U.S. small‑cap sentiment could benefit similar niche manufacturers.
Limited; primarily affects U.S. investors focused on turnaround plays.
Counterpoint
Growth may be unsustainable; margin expansion could stall if demand wanes.
Key entities
- companyEastman Kodak Company
U.S. listed imaging and chemicals firm (KODK).
- companyNeurAxis, Inc.
U.S. listed neuromodulation biotech (NRXS).
